CD markers

Camidanlumab tesirine is an antibody-drug conjugate (ADC) that targets CD25, utilizing the HuMax-TAC human IgG1 monoclonal antibody. This compound is conjugated via a cleavable dipeptide linker to a pyrrolobenzodiazepine (PBD) dimer, achieving a drug-antibody ratio of 2.3. Camidanlumab tesirine demonstrates exceptional affinity for human CD25 at the picomolar level and exhibits potent cytotoxic effects against various CD25-expressing human lymphoma cell lines, positioning it as a promising candidate for targeted cancer therapies.

IGFBP-3 peptide is an 18-amino acid fragment of insulin-like growth factor binding protein-3, known to inhibit the interaction between CD44 and hyaluronan. This peptide effectively binds to Humanin and hyaluronan, thereby blocking their functional interactions. IGFBP-3 peptide serves as a useful tool for researching CD44-related signaling pathways and its role in cellular adhesion and migration.

P8RI is a biomimetic peptide that acts as a CD31 agonist. By binding to the juxtamembrane amino acid sequence of the ectodomain of CD31, P8RI restores the CD31 inhibitory pathway, exhibiting significant immunosuppressive effects. This compound is useful for research applications focused on immune modulation and the exploration of CD31-related pathways in cellular processes.

Girancitug is a humanized IgG1κ monoclonal antibody that specifically targets the vascular endothelial growth factor receptor 2 (VEGFR2/KDR/CD309). It effectively inhibits angiogenesis, making it a valuable tool in cancer research. Girancitug is applicable in anti-angiogenic therapy studies, particularly for cancers such as colorectal and ovarian cancers.

(Z)-Leukadherin-1 is a potent allosteric agonist of CD11b that exhibits oral bioavailability. This compound effectively repolarizes tumor-associated macrophages, diminishes the presence of immunosuppressive myeloid cells within tumors, and enhances the activation of dendritic cells. It serves as a valuable reagent for research in immuno-oncology, exploring mechanisms of immune modulation and macrophage plasticity.

Sulfo-ara-F-NMN is a selective SARM1 activator and CD38 inhibitor, functioning as a mimetic of nicotinamide mononucleotide (NMN). It effectively activates SARM1 while inhibiting CD38, with an IC50 of approximately 10 μM. This compound is valuable for research applications focused on the modulation of intracellular cyclic ADP-ribose (cADPR) production and the exploration of pathways involving SARM1 and CD38 in cellular signaling.

EP 80317 is a selective ligand for CD36. This compound exhibits cardioprotective effects against damage and dysfunction caused by myocardial ischemia and reperfusion, while also temporarily reducing peripheral lipolysis. EP 80317 is valuable in the investigation of cardiovascular disease mechanisms and potential therapeutic interventions.